ERBB2 and breast cancer: Given this information, statistical attempts at adjusting for crossover were made, resulting in a 20% lower risk of death in the combination arm; despite these hurdles, the addition of lapatinib to capecitabine in HER2-positive breast cancer patients continued to be supported [18].